We are live on ! Find out more
BFRIW icon

Biofrontera

1 day
5 days
1 month
3 months
6 months
Year to date
1 year
5 years
10 years
 

About: Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy. The Company's licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (together, the RhodoLED Lamps), are used for the treatment of actinic keratoses (AKs), which are pre-cancerous skin lesions. The company's revenues are derived from within the United States and, therefore, no other geographical segments.

Employees: 94

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 0%
Neutral 100%
Negative 0%
Neutral
GlobeNewsWire
20 hours ago
Biofrontera Announces FDA Approval of Ameluz® Red Light PDT for the Treatment of Superficial Basal Cell Carcinoma
Ameluz used in conjunction with the RhodoLED lamp becomes the first and only photodynamic therapy approved in the United States to treat a skin cancer, creating an additional growth opportunity for Biofrontera's photodynamic therapy platform
Biofrontera Announces FDA Approval of Ameluz® Red Light PDT for the Treatment of Superficial Basal Cell Carcinoma
Neutral
GlobeNewsWire
1 month ago
Biofrontera Inc. Reports Strong Second Quarter 2026 Financial Results Driven by 33% Revenue Growth
WOBURN, Mass., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ: BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT) in dermatology, today reported financial results for the quarter ended June 30, 2026.
Biofrontera Inc. Reports Strong Second Quarter 2026 Financial Results Driven by 33% Revenue Growth
Neutral
GlobeNewsWire
3 months ago
Biofrontera Inc. to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026
WOBURN, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), will participate in a webcast presentation and host one-on-one meetings with investors at the Lytham Partners Spring 2026 Investor Conference, taking place virtually on Thursday, May 28, 2026.
Biofrontera Inc. to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026
Neutral
Seeking Alpha
4 months ago
Biofrontera Inc. (BFRI) Q1 2026 Earnings Call Transcript
Biofrontera Inc. (BFRI) Q1 2026 Earnings Call Transcript
Biofrontera Inc. (BFRI) Q1 2026 Earnings Call Transcript
Price charts implemented using Lightweight Charts™